menu

Quintiles Library

Precision Enrollment
Featured Video
Show Filters
Fact Sheet
Commercial success is about more than just prescription numbers. It’s about getting better clinical outcomes by ensuring that the right patients get access to the right medications, and making sure that they take them correctly. Better patient health is the best measure of achievement. To realize this goal, we have been partnering with clients for more than 15 years with...
Read more
Fact Sheet
Engagement is critical for better patient outcomes, but as many as 56% of healthcare consumers show little or no engagement in their health. Redesigning patient support programs to move them from a transactional approach to one based around patient interactions and relationships could make all the difference.
Read More
Infographic
The number of therapeutic options in cancer care is growing, and with it the complexity of treatment. Doctors are now faced with various decisions and choices from combinations of well-known drugs to precision medicines and personalized treatments, such as immunotherapies or even cell-based therapies. Some may come with complex changes to clinical pathways, or unfamiliar...
Read More
Fact Sheet
Patient expectations and choices are increasingly important in healthcare. However safe and effective a drug is in clinical trials, if patients choose not to take it in the real world, then biopharma, patients and healthcare systems all lose out. Discrete Choice Experiments offers a solution. ‘Discrete Choice Experiments’ (DCE) can help you find out which...
Read More
Fact Sheet
Product launches are notoriously difficult, with most brands not achieving their year one forecast. With so much at stake, being armed with sound strategies and an agile approach to get to market and realize value quickly can make all the difference. With our deep therapeutic and commercial expertise – powered by advanced, actionable analytics – QuintilesIMS helps pave...
Read More
Article
In an article published in the February 2017 issue of International Clinical Trials, Stewart Rosen and Nicola Smith discuss the challenge of patient recruitment for clinical trials and using clinical trial educators to help investigators with enrollment targets. This article is taken from International Clinical Trials February 2017, pages 44-47. © Samedan Ltd
Explore More
Article
Life science companies that are pouring millions of dollars into clinical R&D simply cannot afford a false start. Done right, 3D outsourcing not only speeds market launch but it can also help a new medicine outperform expectations by facilitating rapid and more widespread uptake by healthcare professionals and even patients. Authors: Paul Harney and Steve DeVrieze - IES,...
Explore More
White Paper
Biopharma companies can no longer take for granted that the incremental benefit or improved mode of action of a new therapy will lead to widespread uptake. Patient support programs (PSPs), offered by biopharma, are not yet commonplace, however, where they do exist they must be designed and then evolve to measure outcomes and demonstrate value. This is in response to...
Explore More
Fact Sheet
QuintilesIMS provides a technology solution powered by the Quintiles Infosario® Outcome system to assist registry sponsors in fulfilling the latest QCDR government regulations.
Read More
Fact Sheet
QuintilesIMS is the leading provider of registries and web-based solutions for measuring, improving and reporting on quality of care and patient outcomes. We have worked with medical and surgical specialty societies, associations and health care foundations since 1998 and have a dedicated division focused exclusively on this sector.
Read More
Infographic
Does social media matter to pharma? Only 50% of pharmaceutical companies are listening to their constituents on social media, and even fewer are engaging their targeted audiences. We think social media does matter read this infographic to see why.
Read More
White Paper
Life science companies that are pouring millions of dollars into clinical R&D simply cannot afford a false start. Done right, 3D outsourcing not only speeds market launch but it can also help a new medicine outperform expectations by facilitating rapid and more widespread uptake by healthcare professionals and even patients.
Explore More
White Paper
Recruitment of a sufficiently large number of participants into clinical trials can be a challenge in multiple therapeutic areas, and this has become particularly true for multiple sclerosis trials. For many reasons, the protocols for these trials have become very complex, and hence demanding on participants. A central difficulty in recruitment is identifying eligible...
Explore More
White Paper
Biosimilar products must be structurally and functionally similar to their reference product. This seemingly simple expectation necessitates a unique developmental approach, which is distinct from traditional product development. The emphasis in biosimilar development lies with analytical proof of similarity, as this is the most sensitive tool to detect differences...
Explore More
Infographic
Extraordinary discoveries are transforming the approach to cancer care – and immunotherapy is one of the most promising avenues of research. QuintilesIMS identifies the top 5 challenges in executing immune-oncology clinical trials, and innovative solutions to address those needs.
Read More
White Paper
This insight brief examines the shift of regulatory affairs work to local hubs, which is creating new opportunities for regulatory professionals to work directly with regulators, provide thought leadership input within their respective organizations, and support product development, while leveraging new technologies. Based on market leadership with over 7,000 product...
Explore More
White Paper
The E2B(R2) standard was first adapted in February 2001. Since then, many changes have been made across the countries where it applies. These changes have promoted an update to E2B(R2) with the new E2B(R3) - which will have a major impact on pharmacovigilance systems and processes, particularly on adverse event reporting and collection of data on drugs. Based on...
Explore More
Article
PharmaBoardroom Q&A with Anand Tharmaratnam, President of QuintilesIMS Asia Pacific, about life-sciences in Asia Pac and Singapore's role as a hub for the region.
Explore More
Presentation
Over the past 30 years, our greatest accomplishments in advancing understanding about the safety, effectiveness and value of healthcare interventions have been achieved through the studying of health records for large populations. More recently, access to electronic health records and other electronic data that can be linked or supplemented by other critical information...
Explore More
Presentation
Risk-based monitoring, and its increasing awareness, is widely viewed as a clinical strategy contributing to better quality control, data accuracy and lower costs. The core of risk-based monitoring is Centralized Monitoring, which has evolved through three stages or “waves,” with value increasing at each wave. QuintilesIMS has built and recently launched a technology...
Explore More